This direct share issue to ShapeQ, one of our current main investors, means that Redsense Medical will receive approximately MSEK 9.8 before deduction of costs related to the issue. It should be noted that subscription price exceeded the current market value.

"The investment from ShapeQ is a clear sign of trust and commitment to drive Redsense towards a successful future. It is important to note that this investment is being made at a premium valuation compared to the current share price, reflecting the potential and value appreciation that ShapeQ sees in Redsense Medical. With our unique product we remain committed to improving safety for dialysis patients - and saving lives!" says Eva Walde, Chair of the Redsense Medical Board of Directors.

Redsense is since long well established in theUS and currently having most of the sales in this market. Besides the growth plans for the US, Redsense has a significant potential to increase sales outside the US with the upcoming launch of the Redsense Clamp in Canada, Australia and selected countries in Europe.

"Redsense has been growing sales with a 40% CAGR in the 2017-2023 period despite the headwinds it faced during the COVID 19 pandemic. Now with the launch of the Redsense Clamp close by, which is going to open up new geographies, as well as the introduction of the Home Dialysis Risk Prevention Act, we see many reasons the growth to at least continue and the company turning profitable soon. By providing the only FDA and CE cleared blood leakage system, Redsense is perfectly positioned to capitalize on global growth trends like staff shortage and home treatment. That's why ShapeQ is happy to significantly invest during the current capital increase in order to ensure the expansion of the business and is looking forward to supporting the company further in its bright future." says Johannes Köpple, CEO of ShapeQ GmbH.

"We are very pleased that ShapeQ is taking a larger ownership position which is a clear sign that they share our view of Redsense Medical's potential. With this capital injection we are very well positioned to realize our strategic growth plan with an initial focus on the launch of the Redsense Clamp. In addition, this transaction will provide for other commercial initiatives to accelerate the growth of Redsense. I look forward to getting back to you on our progress. Our journey to improve patient safety continues!" concludes Pontus Nobréus.